Bimekizumab Response Maintenance through Two Years of Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Responded After 16 Weeks: Interim Results from the BE BRIGHT Open-Label Extension Trial. J of Skin 2021, 5 (6), s52. https://doi.org/10.25251/skin.5.supp.52.